Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Feb;27(2):911-919.
doi: 10.1111/dom.16091. Epub 2024 Nov 25.

Inclisiran versus alirocumab in improving lipid profile parameters: A systematic review and meta-analysis

André Saad Cleto  1 , João Matheus Schirlo  1 , Victor Hugo Oliveira Gomes  1 , Maria Luiza Julinhaque Beraldo  1 , Guinter Sponholz Neiverth  1 , Mayara Beltrame  1 , Janete Machozeki  1 , Camila Marinelli Martins  1
Affiliations
Meta-Analysis

Inclisiran versus alirocumab in improving lipid profile parameters: A systematic review and meta-analysis

André Saad Cleto et al. Diabetes Obes Metab. 2025 Feb.

Abstract

Aims: Dyslipidemia is a risk factor for cardiovascular diseases. Some patients are resistant to conventional treatment. In these patients, there is the possibility of using PCSK9 inhibitors. The objective of this systematic review was to compare alirocumab with inclisiran in improving the lipid profile.

Materials and methods: This study was carried out in accordance with Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols Statement (PRISMA) and registered with PROSPERO (CRD42024563261). The following databases were accessed on 2 July 2024: PubMed, Scopus and Web of Science. Clinical trials that evaluated the lipid profile were included. With these data, meta-analyses were carried out seeking to evaluate the difference between the baseline and the 12- and 24-week endpoints.

Results: Initially, 1157 studies were found, of which 32 were included. In total, 30 718 patients participated in the included studies. There was a statistically significant difference, favouring alirocumab 75 mg (-51.54%, 95% confidence interval [CI] -53.43%; -49.66%), in relation to inclisiran 300 mg (-41.34%, 95% CI -50.30%; -31.34%) in reducing low-density lipoprotein cholesterol (LDL-C) (p = 0.05), in relation to inclisiran 200 and 300 mg in reducing total cholesterol (p < 0.01) (p < 0.01) and triglycerides (p = 0.02) (p = 0.04) in 24 weeks. Furthermore, alirocumab 150 mg was superior to both doses of inclisiran in reducing total cholesterol (p < 0.01) (p < 0.01). There was no statistically significant difference in the reduction of lipoprotein(a) by alirocumab 75 mg (-22.35%, 95% CI -24.67; -20.03) and 150 mg (-25.17%, 95% CI -30.94; -19.41) compared to inclisiran 300 mg (-13.37, 95% CI -28.66; 1.93) (p = 0.26) (p = 0.16).

Conclusion: Alirocumab was superior to inclisiran in improving the lipid profile, especially in reducing LDL-C, total cholesterol and triglycerides.

Keywords: dyslipidaemia; endocrine therapy; meta‐analysis; systematic review.

PubMed Disclaimer

References

REFERENCES

    1. Leiter LA, Cariou B, Müller‐Wieland D, et al. Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM‐INSULIN randomized trial. Diabetes Obes Metab. 2017;19(12):1781‐1792.
    1. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097‐2107.
    1. Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37(48):3588‐3595.
    1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713‐1722.
    1. Koren MJ, Rodriguez F, East C, et al. An “Inclisiran first” strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83(20):1939‐1952.

MeSH terms

LinkOut - more resources